IDH -mutant gliomas represent a rare subset of brain tumors, affecting approximately 12% to 20% of adult patients with glioma. 1 Typically diagnosed in younger populations, these tumors generally ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

An ongoing phase 2 trial (NCT07222579) has seen early success with a new subcutaneous formulation of blinatumomab (Blincyto) in a patient with CD19-positive mixed phenotype acute leukemia (MPAL), a ...

Precision oncology represents a fundamental shift in how we treat malignancy. Rather than the broad-spectrum "carpet bombing" of traditional chemotherapy, the field focuses on "identifying a gene, a ...

For 3 decades, the clinical narrative for limited-stage small cell lung cancer (LS-SCLC) was one of grim consistency. Patients diagnosed with this aggressive neuroendocrine malignancy—a disease ...

In this concluding segment, Dr Shaheen focuses on how shared decision making and quality of life considerations guide treatment selection in later line pancreatic neuroendocrine tumor care. She ...

Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid ...

Decreases in circulating tumor DNA (ctDNA) within the first month of immune checkpoint inhibitor (ICI) therapy were strongly ...

The FDA accepted the new drug application for iberdomide based on minimal residual disease negativity benefit shown in the ...

FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...

Why most eligible lymphoma patients miss CAR T: experts urge stronger academic-community handoffs, clearer protocols, and ...

In a significant advancement for thoracic oncology within the Appalachian region, WVU Medicine has announced it is the first ...